Vetoquinol announced that, following positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commissiobn has granted marketing authorisation for Felpreva? (tigolaner/emodepside/praziquantel) for spot-on prevention and treatment of mixed parasitic infestations/infections in cats. Felpreva? is the first spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites including gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a single dose. It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections, including: Endoparasites: Gastrointestinal roundworms: infection with Toxocara cati, Toxascaris leonina and Ancylostoma tubaeforme. Lungworms: infection with Aelurostrongylus abstrusus and Troglostrongylus brevior. Tapeworms: infection with Dipylidium caninum and Taenia taeniaeformis - Ectoparasites: Flea (Ctenocephalides felis), tick (Ixodes ricinus, Ixodes holocyclus) and mite (Otodectes cynotis) infestations, as well as mild to moderate cases of notoedric mange (caused by Notoedres cati). It can also form part of a treatment strategy for flea allergic dermatitis (FAD). Felpreva? is part of the endectocide class of veterinary parasiticides that covers both internal (endo) and external (ecto) parasites. It is a combination of active substances emodepside and praziquantel, with tigolaner, a novel active ingredient. It is estimated that parasiticides make up the largest segment in the companion animal veterinary pharmaceutical market worldwide. Moreover, the fast-growing endectocide category is estimated to make up approximately one quarter of the total companion animal parasiticide market. 50% of pet owners in Europe report currently treating their pets with an endectocide product.3 However, research suggests owners are treating cats less frequently than recommended by the European Scientific Counsel Companion Animal Parasites (ESCCAP), which recommends no less than four times per year for deworming in certain risk groups of cats. It is anticipated that Felpreva? will be made available to veterinarians across Europe in early 2022.